Altered diltiazem metabolism in the neonatal rabbit following intra-uterine chronic exposure to diltiazem

References

• BREGANTE, M. A., ARAMAYONA, J. J, FRAILE, L. J., G-AuciA, M. A. and SOLANS, C., 2000, Diltiazem blood pharmacokinetics in pregnant and non-pregnant rabbits. Maternal and fetal tissue levels. Xenobiotica, 30, 831–841.
   Google Scholar
• FRAILE, L. J., ARAMAYONA, J. J., BREGANTE, M. A., GAuca, M. A. and ABAD IA, A. R., 1996, Deacetylation of diltiazem by several rabbit tissues. Pharmaceutical Research, 13, 1874–1879.
   Google Scholar
• FRAILE, L. J., ARAMAYONA, J. J., GARCIA, M. A. and BREGANTE, M. A., 1997, Enhanced diltiazem deacetylase activity in pre-term and full-term rabbits compared with adult rabbits. Biology of the Neonate, 72, 51–61.
   PubMedGoogle Scholar
• HERMANN, P. and MORSELLI, P. L., 1985, Pharmacokinetics of diltiazem and other calcium channel blockers. Acta Pharmacologica and Toxicologica, 57,10–20.
   PubMedGoogle Scholar
• HOLBROOK, R. H., GIBSON, R. N. and Voss, E. M, 1988, Tocolytic and cardiovascular effects of the calcium antagonist diltiazem in the near-term pregnant rabbit. American Journal of Obstetrics and Gynecology, 159, 591–595.
   PubMedGoogle Scholar
• HOMSY, W., LEFEBVRE, M., CAILLE, G. and Du Somm, P., 1995, Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: in vitro studies. Pharmaceutical Research, 12, 609–614.
   PubMedGoogle Scholar
• HUSSAIN, M. D, Ti, Y. K., GRAY, M. R. and COUTTS, R. T., 1994, Mechanisms of time-dependent kinetics of diltiazem in the isolated perfused rat liver. Drug Metabolism and Disposition, 22, 36–42.
   PubMedGoogle Scholar
• JOS, D. R., GORSKI, J. C., HAMAN, M. A., MAYHEW, B. S., RIDER, S. and HALL, S. D., 1999, Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. Journal of Pharmacology and Experimental Therapeutics, 290, 1116–1125.
   PubMedGoogle Scholar
• KATES, R. E., 1983, Calcium antagonists. Pharmacokinetic properties. Drugs, 25, 113–124.
   PubMedGoogle Scholar
• LEBOEUF, E. and GRECH-BELANGER, O., 1987, Deacetylation of diltiazem by rat liver. Drug Metabolism and Disposition, 15, 122–126.
   Google Scholar
• LEFEBVRE, M., CAILLE, G. and Du Somm, P., 1996, Organ-specific pattern of inhibition of diltiazem metabolism at steady state in rabbits. Journal of Pharmacology and Experimental Therapeutics, 279, 902–907.
   PubMedGoogle Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MURRAY, M. and BUTLER, A. M., 1996, Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. Journal of Pharmacology and Experimental Therapeutics, 279, 1447–1452.
   PubMedGoogle Scholar
• Nouvvs, J. F. M., 1992, Pharmacokinetics in immature animals: a review. Journal of Animal Science, 70, 3627–3634.
   PubMedGoogle Scholar
• PICHARD, L., GILLET, G., FABRE, I., DALET-BELUCHE, I., BONIS, C., THENOT, J. P. and MAUREL, P., 1990, Identification of the rabbit and human cytochromes P-45011IA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metabolism and Disposition, 18, 711–719.
   Google Scholar
• RENTON, K. W., 1985, Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochemical Pharmacology, 34, 2549–2553.
   PubMedGoogle Scholar
• SCHWARK, W. S., 1992, Factors that affect drug disposition in food-producing animals during maturation. Journal of Animal Science, 70, 3635–3645.
   PubMed Web of Science ®Google Scholar
• SUGAWARA, Y., NAKAMURA, S., USUKI, S., ITO, Y., SUZUKI, T., OHASHI, M. and HARIGAYA, S., 1988, Metabolism of diltiazem. II. Metabolic profile in rat, dog and man. Journal of Pharmacobiodynamics, 11, 224–233.
   PubMedGoogle Scholar
• SUTTON, D., BUTLER, A. M., NADIN, L. and MURRAY, M., 1997, Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. Journal of Pharmacology and Experimental Therapeutics, 282, 294–300.
   PubMed Web of Science ®Google Scholar
• WEIR, M. R., 1995, Diltiazem: ten years of clinical experience in the treatment of hypertension. Journal of Clinical Pharmacology, 35, 220–232.
   PubMed Web of Science ®Google Scholar
• YABANA, H., NAGAO, T. and SATO, M., 1985, Cardiovascular effects of the metabolites of diltiazem in dogs. Journal of Cardiovascular Pharmacology, 7, 152–157.
   PubMed Web of Science ®Google Scholar
• YEUNG, P. K. F., FENG, J. Z. and BUCKLEY, S. J., 1998, Pharmacokinetics and hypotensive effect of diltiazem in rabbits: comparison of diltiazem with its major metabolites. Journal of Pharmacy and Pharmacology, 50, 1247–1253.
   Google Scholar
• YEUNG, P. K. F., MoNTAGuE, T. J., Tsui, B. and MCGREGOR, C., 1989, High-perfomance liquid chromatographic assay of diltiazem and six of its metabolites in plasma: application to a pharmacokinetic study in healthy volunteers. Journal of Pharmaceutical Science, 78, 592–597.
   Google Scholar
• YEUNG, P. K. F., MOSHER, S. J., QUILLIAM, M. A. and MONTAGUE, T. J., 1990, Species comparison of pharmacokinetics and metabolism of diltiazem in humans, dogs, rabbits and rats. Drug Metabolism and Disposition, 18, 1055–1059.
   Google Scholar